Health Care M&A Will Continue, But One Company's Strategy Shines

Mergers and acquisitions within the health care space dominated the headlines this year, and while the trend is set to continue into 2015, Jim Cramer says one company in particular has a brilliant method. While we saw mergers and acquisitions within the sector occur for a variety of individual reasons, Cramer says he's a believer in Celgene's strategy and believes that will take its stock higher through the end of the year. He details the company's method and his expectation that it will take its 15% stake in Agios Pharma to a 100% takeout. Many eyes will also be on AbbVie to see what deals it makes after backing out of its $54 billion acquisition of Shire. It will also remain to be seen whether Bristol-Myers Squibb will finally seal its rumored deal for Shire in 2015.